The acceleration of AI in Life Sciences: Insights from BiotechX Europe

“We are particularly excited about the potential of AI in Life Sciences and how it can drive societal well-being. We are excited to bring this impact across the whole value chain, from Research and Development to Manufacturing as well as various compliance and market access workflows,” said Alen Arslanagic, Founder & CEO of Visium.

A new era of AI in Life Sciences

After three energizing days at BioTechX Europe, one thing is clear – AI is transforming Life Sciences at an unprecedented speed. 

‍

At Visium’s booth, leaders from Roche, Novartis, Novo Nordisk, Boehringer Ingelheim, Ferring, and many others joined us to explore how AI can accelerate discovery, improve patient outcomes, and bring life-changing breakthroughs to patients faster.

These conversations naturally evolved into deeper discussions about how to make AI truly work in high-stakes environments, not just as innovation, but as a trusted, compliant part of the Life Sciences value chain. 

From challenges to real-world solutions in Life Sciences

During our roundtable session, pharma executives openly discussed the regulatory and compliance barriers that continue to slow down AI adoption. 

The conversation quickly shifted from challenges to solutions as we explored practical ways forward. It was inspiring to see a collective agreement that the future of AI in Life Sciences will be built on trust, transparency, and collaboration between technology and regulation.

Our keynote presentation demonstrated the real-world AI transformation in Life Sciences. We showcased a practical example of how AI is reshaping protein design by flagging risk early, accelerating lead selection, and bringing predictability to what once was pure experimentation. 

How to operationalize high-stakes AI use cases in Life Sciences

The highlight of the event was seeing pharma leaders react to the reveal of Visium’s new AI platform, developed to operationalize high-stakes use cases and deliver 10X the value at a fraction of the cost while maintaining full transparency and compliance. 

Behind it all is Agentic AI and our approach to building systems that think, verify, and scale safely. This next-generation approach enables organizations to move from proof of concept to enterprise-scale deployment, bridging the gap between experimentation and measurable impact.

Why we build AI and why it matters



For us at Visium, it’s not only about how we build AI, but why.

Because the ultimate purpose of every algorithm we design is to help organizations unlock value at scale, accelerate innovation, and improve lives.

Looking ahead: The future of AI in Life Sciences

As the boundaries of what’s possible continue to expand, one question remains at the center of every boardroom discussion: Where does AI create the most untapped potential in Life Sciences, and what’s still holding it back?

We would love to hear your perspective. Join conversations and share your perspective with our team, or drop us a comment on LinkedIn. 

‍